Reneo Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
Reneo Pharmaceuticals Achieves Target Enrollment in the Pivotal STRIDE Study of Mavodelpar in Primary Mitochondrial Myopathies
Reneo Pharmaceuticals to Present Preclinical Mavodelpar Data at the Society for Inherited Metabolic Disorders Annual Meeting 2023
Nine Mile Metals Announces Certified Assays from DDH-WD-25-01 of 3.83% CuEq Over 22.65 Meters (39.52 g/t Ag, 0.96 g/t Au, 0.99% Cu, 2.25% Pb, 1.61% Zn) and 4.33% CuEq Over 17.65 Meters (42.5 g/t Ag, 1.01 g/t Au, 1.2% Cu, 2.62% Pb, 2.05% Zn) Including 1.21 g/t Au and 50.33 g/t Ag Over 13.00 Meters
